Financial Information

These accounts have been produced by chartered accountants and reviewed by our statutory auditor Deloitte & Associates. The following figures (Revenue, 5 594 k€ - Expenses 5 384 k€) do not include provisions.

Revenue 2016
.
Expenses 2016

EURORDIS Expenses 2017

Collapse All
Expand All
Expenses Amount (€) Percentage
Staff 2 679 121 50%
Volunteers 1 027 105 19%
Logistics 803 912 15%
Services 752 538 14%
Purchase 104 751 2%
Miscellaneous 17 034 0%
Sub-total 5 384 461 100%
Contingency and loss provisions 57 898 1%
Total Expenses 5 442 359  
Result 175 854

 

EURORDIS Revenue 2017

Collapse All
Expand All
Revenue Amount (€) Percentage
Patient Organisations 882 796 16%
Individuals 1 038 157 19%
European Commission 1 392 730 25%
Corporates 1 788 093 32%
Not for Profit Organisations 25 000 0%
Event Fees 112 721 2%
Miscellaneous 354 367 6%
Sub-total 5 593 863 100%
Recovery of provisions 24 350  
Total Revenue 5 618 213  

EURORDIS Corporate Revenue 2017

Collapse All
Expand All

Pharmaceutical & Biotechnology Companies

Company Amount (€) % of Revenue
ABLYNX 10 000 0,18%
ACHILLION 26 000 0,46%
ACTELION 45 000 0,80%
AEGERION 5 000 0,09%
AGIOS 5 000 0,09%
AKCEA 10 000 0,18%
ALEXION 25 000 0,45%
ALNYLAM 35 000 0,63%
AMGEN 5 000 0,09%
AMICUS THERAPEUTICS 15 000 0,27%
ASTRAZENECA 10 000 0,18%
AUDENTES 10 000 0,18%
AVEXIS 10 000 0,18%
BAYER 5 000 0,09%
BIOGEN 52 862 0,94%
BIOMARIN 30 000 0,54%
BLUEBIRD BIO 10 000 0,18%
BOEHRINGER INGELHEIM 10 000 0,18%
BRISTOL-MYERS SQUIBB 10 000 0,18%
CELGENE 100 000 1,79%
CHIESI 40 000 0,72%
CLEMENTIA 18 750 0,34%
CSL BEHRING 78 500 1,40%
CYTOKINETICS 30 000 0,54%
DOMPE 5 000 0,09%
EDITAS 5 000 0,09%
ENZYVANT 5 000 0,09%
GRIFOLS 10 000 0,18%
GSK 70 000 1,25%
HELSINN 15 000 0,27%
HORIZON 31 000 0,55%
ICON 5 000 0,09%
INCYTE 10 000 0,18%
INSMED 5 000 0,09%
IPSEN 10 000 0,18%
JAZZ PHARMA 10 000 0,18%
KYOWA KIRIN 10 000 0,18%
LEADIANT BIOSCIENCES 8 000 0,14%
LFB BIOMEDICAMENTS 10 000 0,18%
LYSOGENE 2 000 0,04%
MSD EUROPE 10 000 0,18%
NOVARTIS 80 000 1,43%
ORPHAN EUROPE 30 000 0,54%
OVID THERAPEUTICS 5 000 0,09%
PFIZER 130 000 2,32%
PHARMA MAR 5 000 0,09%
PROMETIC LIFE SCIENCES 5 000 0,09%
PTC 35 000 0,63%
REGENXBIO 5 000 0,09%
ROCHE 45 000 0,80%
SANGAMO 5 000 0,09%
SANOFI GENZYME 60 000 1,07%
SANTHERA 5 000 0,09%
SHIRE 130 000 2,32%
SOBI 30 000 0,54%
SPARK THERAPEUTICS 5 000 0,09%
STALLERGENES GREER 8 000 0,14%
SYNEOS HEALTH 10 000 0,18%
TAKEDA 42 896 0,77%
UCB 5 000 0,09%
ULTRAGENYX 28 750 0,51%
VERTEX 90 000 1,61%
VIFOR PHARMA 5 000 0,09%
WAVE LIFE SCIENCES 10 000 0,18%
Grand Total 1 591 758 28,46%

Other Health Sector Companies

Company Amount (€) % of Revenue
CYDAN II 5 000 0,09%
CLINIGEN 5 000 0,09%
MAPI 28 147 0,50%
INCEPUA 5 000 0,09%
OPENAPP 5 000 0,09%
QuintilesIMS-IQVIA 25 000 0,45%
VITRO SOFTWARE 5 000 0,09%
CLINIGEN 10 000 0,18%
MK&A 3 000 0,05%
Total 100 189 1,79%

Corporates Outside the Health Sector

Company Amount (€) % of Revenue
MICROSOFT 15 000 0,27%
BURSON MARSTELLER 5 000 0,09%
DLA PIPER 6 500 0,12%
MEDIA PLANET 14 225 0,25%
GOOGLE 5 963 0,11%
PUBLICIS LIFEBRAND 35 760 0,64%
REFLEX MEDIA 11 175 0,20%
TRANSLATORS WITHOUT BORDERS 3 048 0,04%
TROMMONS 3 048 0,05%
MISCELLANEOUS 439 0,01%
Total 100 189 1,79%


*Cutoff is the of deferred income and brought forward. For example, in the context of a special event, when a donation is made the year before the event, part of the donation is used to cover some of the preparatory costs of the event and the rest is put aside for the following year.

» 2017 financial independence form.
» EURORDIS Policy on Financial Support by Commercial Companies  

In addition to the organisations accredited (on the right-hand side), EURORDIS gratefully acknowledges the generous support of the following contributors in 2017:

Health Sector Corporates

Diversification of funding is key to minimising potential conflict of interest with donors. EURORDIS has diversified its pharmaceutical and biotechnology sector contributors from 53 to 64 different companies in 2017. Eight other health sector companies also contributed to the 2017 incomes. Companies have supported EURORDIS through the EURORDIS Round Table of Companies , the EURORDIS Membership Meeting Budapest 2017, the Multi-Stakeholder Symposium, the EURORDIS Black Pearl Awards , as well as international initiatives such as Rare Disease Day, Rare Barometer , RareConnect™ , Rare Diseases International and the co-funding of DG SANTE Joint Action of Rare Cancers. The breakdown of each company’s donations by project is detailed on the EURORDIS website on the “Corporate revenue” tab of the “Financial Information” section.

Top five donors

1.Pfizer
Shire
3.Celgene
4.Vertex
5.Novartis

Other Pharmaceutical Companies & Health Sector Corporates

Ablynx Achillion Actelion Aegerion Agios Akcea Alexion Alnylam AMGEN Amicus Therapeutics AstraZeneca Bayer Schering Pharma AG Avexis Bayer Schering Pharma AG Biogen Idec Biomarin BlueBird Bio boehringer-ingelheimBMS Chiesi Clementia Clinigen CSL Behring Cydan Cytokinetics Dompe Farmaceutici Editas Enzyvant Grifols GSK Helsinn Horizon Pharma USA ICON Inceptua Incyte Helsinn Ipsen IQVIA Jazz pharmaceuticals Kyowa Kirin Leadiant LFB Lysogene-Q MAPI MK&A MSD OpenApp Orphan Europe OVID Pharmamar prometic PTC Therapeutics RegenXBio Roche Sangamo Sanofigenzyme Santhera UCB Spark Stallergener Greer Syneos Health UCB UCB Ultragenyx Vifor VitroSoftware Wave

In-kind contributors

Burson-Marsteller DLA PiperGoogleMedia PlanetPublicis Health ReflexVerlag Rosetta FoundationTranslators without borders

Other contributors

AIPM Logo

AIPM

Association of International Pharmaceutical Manufacturers

Kindness for Kids

Kindness for Kids

 
 
La voix des patients atteints de maladies rares en EuropeEURORDIS Donnant la voix, à l'international, aux personnes vivant avec une maladie rare, Rare Diseases International est une initiative d'EURORDISRare Disease International Pour rapprocher patients, familles et experts sur un forum modéré multilingue, où partager leurs expériences. RareConnect est une initiative d'EURORDIS RareConnect Le programme Rare Barometer est une initiative d’EURORDIS qui vise à réaliser des sondages pour transformer les expériences des patients de maladie rare en faits et chiffres à communiquer aux décideurs politiques.Rare Barometer Campagne internationale de sensibilisation organisée chaque année le dernier jour de février, la Journée Internationale des Maladies Rares est une initiative d'EURORDISRare Disease Day Participez au plus grand événement réunissant tous les acteurs des maladies rares en Europe lors de Conférence européenne bisannuelle sur les maladies rares et les médicaments orphelins (European Conference on Rare Diseases and Orphan Products, ou ECRD). L'ECRD est une initiative d'EURORDISEuropean Conference on Rare Diseases